Financial Performance - In the 2024 annual report, the company reported total revenue of 569 million yuan, a year-on-year decrease of 3.95% [2] - The net profit attributable to shareholders was a loss of 215 million yuan, an improvement from a loss of 347 million yuan in the same period last year [2] - The net cash flow from operating activities was -202 million yuan, compared to -351 million yuan in the previous year [2] - The basic earnings per share were -0.39 yuan, with a weighted average return on equity of -19.89% [2][22] Valuation Metrics - As of the closing price on April 24, the company's price-to-book ratio (TTM) was approximately 1.56 times, and the price-to-sales ratio (TTM) was about 3.28 times [2] Revenue Composition - The company's revenue for 2024 was primarily derived from self-developed SaaS products in clinical research, drug safety, and pharmaceutical marketing, with digital services contributing significantly [10][18] Cash Flow and Financing - The net cash flow from financing activities was 281 million yuan, an increase of 320 million yuan year-on-year [26] - The net cash flow from investment activities was -284 million yuan, compared to 238 million yuan in the same period last year [26] Asset and Liability Changes - As of the end of 2024, the company's trading financial assets decreased by 56.99%, while cash and cash equivalents increased by 17.2% [32] - Contract liabilities decreased by 36.89%, while lease liabilities increased significantly by 377.63% [35] Liquidity Ratios - The company's current ratio was 5.05, indicating a strong liquidity position [39]